<DOC>
	<DOCNO>NCT01043393</DOCNO>
	<brief_summary>The objective study evaluate potential desoximetasone 0.25 % topical spray suppress HPA axis function . The potential adrenal suppression assess follow multiple dose Desoximetasone 0.25 % Topical Spray patient moderate severe plaque psoriasis . The secondary objective evaluate efficacy parameter evaluate adverse event ( AE ) profile .</brief_summary>
	<brief_title>Desoximetasone Spray 0.25 % , Hypothalamic Pituitary Adrenal ( HPA ) Axis Study</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Desoximetasone</mesh_term>
	<criteria>Have definite clinical diagnosis stable plaque psoriasis extent BSA affect designated group Group 1 : involvement 1015 % BSA Group 2 : involvement &gt; 15 % BSA Have Physicians Global Assessment ( PGA ) score 3 ( moderate ) 4 ( severe ) baseline overall disease severity . Results cortisol response test consider normal show evidence abnormal HPA function adrenal response . Patients must fulfill stipulation : Female pregnant , nursing , plan become pregnant duration study , child bear potential sexually active prepare use appropriate contraceptive method avoid pregnancy . Patient current diagnosis type psoriasis stable plaque psoriasis ( i.e . acute , guttate , erythrodermic , exfoliative pustular psoriasis ) psoriasis kind face scalp require active treatment study . Patient history psoriasis unresponsive topical corticosteroid therapy . In Investigator 's opinion , patient dermatological condition , atopic contact dermatitis , may interfere clinical assessment sign symptom psoriasis Patient history allergy sensitivity corticosteroid history drug hypersensitivity intolerance , opinion Investigator , would compromise safety patient result study . Patient history adverse reaction CortrosynTM similar test reagent . Patient significant history current evidence chronic infectious disease , system disorder , organ disorder medical condition Investigator 's opinion would place study patient undue risk participation study . Patient currently receive receive radiation therapy , antineoplastic agent immunosuppressant medication within 4 week prior first dose study drug . Patient undergone treatment systemic photo antipsoriatic therapy within 8 week first dose study drug . Patient treat within 12 week ( five half live whichever less ) prior first dose study drug biological therapy psoriasis . Patient receive systemic steroid within 4 week first dose study drug . Patients use topical antipsoriatic agent kind topical corticosteroid reason within 2 week prior first use study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Plaque psoriasis</keyword>
</DOC>